Selection	O
of	O
a	O
common	O
multipotent	O
cardiovascular	O
stem	O
cell	O
using	O
the	O
3	B-PROMOTER
.	I-PROMOTER
4	I-PROMOTER
-	I-PROMOTER
kb	I-PROMOTER
MesP1	I-PROMOTER
promoter	I-PROMOTER
fragment	E-PROMOTER
.	O


Common	O
cardiovascular	O
progenitor	O
cells	O
are	O
characterized	O
and	O
induced	O
by	O
expression	O
of	O
the	O
transcription	O
factor	O
MesP1	O
.	O


To	O
characterize	O
this	O
population	O
we	O
used	O
a	O
3	B-PROMOTER
.	I-PROMOTER
4	I-PROMOTER
-	I-PROMOTER
kb	I-PROMOTER
promoter	I-PROMOTER
fragment	E-PROMOTER
previously	O
described	O
by	O
our	O
group	O
.	O


This	O
served	O
to	O
isolate	O
MesP1	O
-	O
positive	O
cells	O
from	O
differentiating	O
ES	O
stem	O
cells	O
via	O
magnetic	O
cell	O
sorting	O
based	O
on	O
a	O
truncated	O
CD4	O
surface	O
marker	O
.	O


As	O
this	O
proximal	B-PROMOTER
promoter	I-PROMOTER
fragment	E-PROMOTER
omits	O
a	O
distal	O
non	O
-	O
cardiovasculogenic	O
enhancer	O
region	O
,	O
we	O
were	O
able	O
to	O
achieve	O
a	O
synchronized	O
fraction	O
of	O
highly	O
enriched	O
cardiovascular	O
progenitors	O
.	O


These	O
led	O
to	O
about	O
90	O
%	O
of	O
cells	O
representing	O
the	O
three	O
cardiovascular	O
lineages	O
:	O
cardiomyocytes	O
,	O
endothelial	O
cells	O
and	O
smooth	O
muscle	O
cells	O
as	O
evident	O
from	O
protein	O
and	O
mRNA	O
analyses	O
.	O


In	O
addition	O
,	O
electrophysiological	O
and	O
pharmacological	O
parameters	O
of	O
the	O
cardiomyocytic	O
fraction	O
show	O
that	O
almost	O
all	O
correspond	O
to	O
the	O
multipotent	O
early	O
/	O
intermediate	O
cardiomyocyte	O
subtype	O
at	O
day	O
18	O
of	O
differentiation	O
.	O


Further	O
differentiation	O
of	O
these	O
cells	O
was	O
not	O
impaired	O
as	O
evident	O
from	O
strong	O
and	O
synchronous	O
beating	O
at	O
later	O
stages	O
.	O


Our	O
work	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
earliest	O
cardiovasculogenic	O
events	O
and	O
may	O
become	O
an	O
important	O
prerequisite	O
for	O
cell	O
therapy	O
,	O
tissue	O
engineering	O
and	O
pharmacological	O
testing	O
in	O
the	O
culture	O
dish	O
using	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
as	O
well	O
as	O
directly	O
reprogrammed	O
cardiovascular	O
cell	O
types	O
.	O


Likewise	O
,	O
these	O
cells	O
provide	O
an	O
ideal	O
source	O
for	O
large	O
-	O
scale	O
transcriptome	O
and	O
proteome	O
analyses	O
.	O
